Abstract No. 297 - Comparison of miriplatin-lipiodol suspension and cisplatin-lipiodol suspension: the antitumor efficacy and safety of transcatheter arterial chemoembolization for hepatocellular carcinoma

Abstract

To compare retrospectively the short-term antitumor efficacy and safety of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with cisplatin-lipiodol suspension (C-LS) and miriplatin-lipiodol suspension (M-LS). Of patients who underwent TACE for unresectable HCCs between January 2010 and August 2011, 25 and 21 patients underwent TACE using C-LS and M-LS, respectively. The short-term antitumor efficacy of both groups was evaluated by the treatment effect (TE) on the CT or MRI images of tumor nodules 3 months after TACE. Adverse events were evaluated to compare both groups. 3 months After TACE using C-LS and M-LS, TE4 (TE4: 100% necrosis or tumor size reduction) was achieved in 30 and 18 tumor nodules, respectively (81% versus 53%; P = 0.006). Objective responses were achieved in 30 nodules exposed to TACE using C-LS and 17 exposed to TACE using M-LS (81% versus 50%; P = 0.011). Disease control was achieved in 36 nodules exposed to C-LS and 27 exposed to M-LS (97% versus 79%; P = 0.017). The percentage of patients attaining TE4, objective response, and disease control was significantly greater in the C-LS group than in the M-LS group. No significant differences were found in the aspartate aminotransferase, alanine aminotransferase, total bilirubin, and creatinine levels between the 2 groups either before or 1 month after treatment. The short-term antitumor efficacy of TACE with C-LS was superior to those with M-LS in terms of the TE4, objective response, and disease control rates. C-LS and M-LS could be used safely for TACE treatment.